keine Finanzberatung

EW · Edwards Lifesciences

Structural-heart devices — the TAVR heart-valve pioneer

Risiko 4/10 · LOW-MODERATE RISK · single-franchise medtech · $89.90 ▲ 0.13%Von KI geschrieben

Stand der Zahlen: · Quellen: öffentliche Markt-Aggregatoren

Kennzahlen

  • Price $89.90
  • Market cap $51.8B
  • P/E (ttm) 53.51
  • Div yield none
  • 52-wk range $72.30 – $96.29
  • Index rank #227 / —

Wichtigste Risiken

  • TAVR growth matures in its core markets (Shareholders) — MED
  • Medtronic and Abbott close the technology gap (Shareholders) — MED
  • Premium valuation on a decelerating core franchise (Shareholders) — MED
  • Clinical setbacks in mitral and tricuspid programs (Patients) — MED

Fazit

A quality pure play, but you pay up front for growth that has to arrive on schedule.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.

⚠️ Independent research for a video, not financial advice. Figures from public sources/aggregators, can be stale; risk scores are editorial estimates. Verify before relying on any of it.